Sitagliptin, Metformin and Glimepiride Fixed‐Dose Combination Compared to Co‐Administration of Metformin and High‐Dose Glimepiride in Indian Patients With Type 2 Diabetes: A Randomised, Double‐Blind, Double‐Dummy, Phase 3 Clinical Study Authors: Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebarao Patil, Ambrish C., Satish Babu K. N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, Pradeep Kumar Rai, Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge, Piyush Patel, Lalit Lakhwani, Suyog Mehta, Sadhna Joglekar Published: 2026 ABSTRACT ABSTRACTAimsThis study assessed the efficacy and safety of a triple fixed‐dose combination (FDC) of sitagliptin, metformin, and glimepiride versus co‐administered metformin and glimepiride in Indian patients with uncontrolled Type 2 diabetes (T2D).Materials and MethodsIn this Phase 3, randomised, double‐blind, double‐dummy study, adult patients with T2D and glycated haemoglobin (HbA1c) of 8%–11%, despite treatment with metformin and glimepiride, were randomised 1:1 to triple FDC of sitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg (SITA + MET + GLIM group) or metformin 1000 mg and glimepiride 2 mg (Co‐administration group) for 16 weeks. Patients assigned to the SITA + MET + GLIM group could continue treatment for a 12‐week open‐label period. The primary endpoint was the change in HbA1c from baseline to Week 16.ResultsOverall, 190 patients were randomised to the SITA + MET + GLIM group and 202 to the Co‐administration group. The least squares mean (standard error) change from baseline in HbA1c at Week 16 was −1.79 (0.07%) in the SITA + MET + GLIM group and −1.27 (0.06%) in the co‐administration group (estimated treatment difference −0.51; 95% confidence interval [CI] −0.69 to −0.33; p < 0.0001). The proportion of patients with HbA1c below 7% at Week 16 was 32.1% in the SITA + MET + GLIM group and 12.6% in the Co‐administration group (p < 0.0001). Adverse events occurred in 25 patients (13.2%) in the SITA + MET + GLIM group and 30 patients (14.9%) in the Co‐administration group.ConclusionsThe triple FDC was superior to co‐administered metformin and high‐dose glimepiride for achieving glycaemic control and was well tolerated in Indian patients with T2D.Trial RegistrationClinical Trials Registry–India identifier: CTRI/2021/11/038169 (registered on 22 November 2021); URL: https://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjI1Mjk=&Enc=&userName= Introduction In 2021, there were an estimated 101 million people with Type 2 diabetes (T2D) and 135 million with pre‐diabetes in India [1]. While the prevalence of this chronic metabolic disease may have peaked in some of the more socioeconomically developed states in India, most of the less developed states remain in the initial take‐off phase [1]. The treatment of cardiovascular disease and other chronic complications of long‐term, uncontrolled diabetes, such as kidney, foot and eye disease, presents a high economic burden to individuals and society [1]. The Impact India programme demonstrated that the average glycated haemoglobin (HbA1c) level in Indian patients with T2D was 8.56%, exceeding the recommended HbA1c level (< 7%) [2]. Hence, an intensive approach to tightly control glycaemic parameters from an early stage is essential [3, 4, 5]. However, awareness of T2D in Indian society remains suboptimal. Although > 30% of patients with T2D in India receive multiple medications, their diabetes remains uncontrolled [6]. Indeed, only 67% of patients with T2D adhere to treatment, with polypharmacy being a key reason for non‐adherence [7]. International guidelines recommend initial therapy with a combination of glucose‐lowering agents in patients with HbA1c > 8.5% at T2D diagnosis and when a stepwise approach would delay access to agents providing cardiorenal protection. However, the addition of multiple medications is associated with an increased pill burden [8]. Fixed‐dose combinations (FDCs) have been shown to improve patients' adherence to treatment [9]. Metformin (a biguanide), glimepiride (a sulfonylurea), and sitagliptin [a dipeptidyl peptidase‐4 inhibitor (DPP‐4i)] are oral treatments with proven efficacy, safety and tolerability in T2D [10, 11, 12]. A survey among Indian healthcare professionals that assessed the usage pattern of glimepiride and metformin FDC for managing T2D found that 64.7% of patients were also prescribed DPP‐4i [13]. Two pilot studies and one mechanistic study in Japanese patients with T2D showed that the glimepiride dose can be reduced when sitagliptin is added to the regimen [14, 15, 16]. A combination of sitagliptin with low‐dose glimepiride reduced HbA1c levels without hypoglycaemia or weight gain. This combination also appeared to preserve beta‐cell function compared to high‐dose glimepiride. The underlying synergy may be based on an increase in cyclic adenosine monophosphate (cAMP) levels induced by incretin therapy, potentiating ATP‐sensitive potassium (KATP) channel‐independent insulinotropic action of glucose. Hence, combining low‐dose glimepiride with sitagliptin and metformin to manage uncontrolled T2D may offer an advantage over high‐dose glimepiride and metformin in preserving beta‐cell function [17]. Therefore, this Phase 3, randomised, active‐controlled, double‐blind study was conducted to assess the efficacy (establishing superiority) and safety of a triple FDC of sitagliptin, metformin and low‐dose glimepiride compared with co‐administration of metformin and high‐dose glimepiride in Indian patients with T2D uncontrolled with metformin and glimepiride. Materials and Methods Study Design This was a Phase 3, multicentre, randomised, parallel, active‐controlled, double‐blind, double‐dummy study conducted at 16 hospitals across eight states in India (Table S1). The study comprised a 2‐week screening period, followed by a 16‐week double‐blind, double‐dummy treatment period and a 12‐week, open‐label treatment period (Figure S1). The trial is registered with the Clinical Trials Registry–India (CTRI/2021/11/038169; registration date: 22 November 2021) and was conducted in accordance with the ethical principles of the Declaration of Helsinki. Ethical approval was obtained from the institutional ethics committee at each study site, and all patients provided written informed consent. Study Participants The study enrolled male and female patients aged 18–65 years diagnosed with T2D, having a body mass index of < 45.0 kg/m2 and on a diet and exercise regimen. Eligible patients had HbA1c levels between 8% and 11% after being on a stable daily dose of glimepiride 4 mg and metformin ≥ 1500 mg for ≥ 10 weeks before screening. Exclusion criteria were known hypersensitivity to sitagliptin, metformin or glimepiride or to drugs of similar chemical classes; Type 1 diabetes diagnosis; a fasting blood glucose (FBG) level ≥ 270 mg/dL at screening; significant renal impairment (estimated glomerular filtration rate < 45 mL/min/1.73 m2), hepatic impairment (aspartate transaminase and alanine transaminase > 3 × upper limit of normal), or history of heart failure. Full inclusion and exclusion criteria are detailed in the Supporting Information. Randomisation and Masking Eligible patients were assigned to study treatment using a computer‐generated randomisation schedule prepared using Statistical Analysis Software (SAS), version 9.4. Site‐wise block randomisation was done using a block size of 04. Each patient was assigned a unique study randomisation number by study‐site personnel (ascending consecutive order within each site). To maintain double‐blinding, study treatments were provided in double‐dummy kits containing a matching placebo. Procedures Eligible patients were randomised (1:1) to receive a triple FDC of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg and glimepiride 1 mg (manufactured by Sun Pharma) twice daily (BID) [SITA + MET + GLIM group] or co‐administration of metformin hydrochloride 1000 mg and glimepiride 2 mg BID (two tablets of metformin 500 mg and one tablet of glimepiride 2 mg) [Co‐administration group]. The treatment was administered for 16 weeks as double‐blind, double‐dummy medication kits. Matching placebos were included in the treatment kits to ensure double‐blinding. After 16 weeks, patients in the Co‐administration group completed the study. Patients in the SITA+MET+GLIM group were eligible to continue in the single‐arm, open‐label 12‐week treatment period. Patients with HbA1c ≥ 8% at week 16 received the same FDC with an up‐titrated dose of glimepiride 2 mg. Treatment compliance was assessed using patient diary entries and confirmed via pill counts. Patients were provided with a glucometer for self‐monitoring of blood glucose at least once a week and as needed. An independent data safety monitoring board (two clinicians, one pharmacologist and an independent statistician) periodically reviewed patients' safety data. The board performed a safety assessment upon completion of the 16‐week double‐blind treatment period for 120 patients before authorising the completion of recruitment and continuation to the 12‐week open‐label treatment period. Endpoints The primary endpoint was the mean change in HbA1c from baseline to Week 16. Secondary efficacy endpoints were the change in HbA1c from baseline to Week 28, proportion of patients with HbA1c < 7% (< 53 mmol/mol) at Weeks 12, 16 and 28, changes in FBG and post‐prandial blood glucose (PPBG) from baseline to Weeks 12, 16, 24, and 28, and the number of patients requiring hypoglycaemia management or rescue medications. Hypoglycaemia was defined as blood glucose ≤ 70 mg/dL (≤ 3.9 mmol/L) or signs and symptoms of hypoglycaemia. Mild hypoglycaemia was defined as blood glucose ≥ 54 mg/dL (≥ 3.0 mmol/L) but < 70 mg/dL (< 3.9 mmol/L). Assessments at Weeks 24 and 28 were only conducted in patients receiving sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 or 2 mg (triple FDCs) during the open‐label treatment period. Safety endpoints included vital signs, clinical laboratory parameters and adverse events (AEs). Preferred terms were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 24.0. Severity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Statistical Analysis A sample size of 392 (196:196) patients was required to provide a power of 80% to detect a difference in mean HbA1c of 0.3% points between the treatment groups at a two‐sided significance level of 0.05, assuming a standard deviation (SD) of 1% and a 10% dropout rate. Patient baseline characteristics were summarised for all randomised patients who received ≥ 1 dose of study medication (safety population). Efficacy analyses included all randomised patients who received ≥ 1 dose of study medication during the double‐blind treatment period and returned for ≥ 1 post‐baseline evaluation visit (modified intention‐to‐treat population). Continuous variables were summarised with mean (SD) for each group. For analysis of the primary efficacy endpoint, a mixed model for repeated measures (MMRM) was used to test for a significant difference between treatment groups. Change in HbA1c was the dependent variable. Treatment, visit, and treatment‐by‐visit interaction were the fixed effects, and baseline HbA1c was the covariate. For primary endpoint, missing data were imputed using the multiple imputation method. A separate sensitivity analysis (using the same MMRM model) was conducted for imputed data. Change from baseline in mean HbA1c at Week 24 and Week 28 was analysed using a Wilcoxon signed‐rank test for within‐group comparisons. The actual values and mean changes in FBG and PPBG from baseline to Weeks 12, 16, 24 and 28 were summarised, assessed for normality, and analysed using MMRM for between‐group comparisons. Proportion of patients achieving HbA1c levels < 7.0% at Weeks 12, 16 and 28 was presented as frequencies and percentages. Chi‐square test was used to determine the significance between treatment groups. The open‐label period assessed the efficacy and safety of the two triple FDC doses (sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg and sitagliptin 50 mg/metformin 1000 mg/glimepiride 2 mg) pooled together. The statistical analyses were performed using SAS, version 9.4. Results Patient Disposition and Baseline Characteristics The study enrolment, randomisation and retention are shown in Figure 1. The first patient was screened on 2 December 2021, and the last treatment was on 27 May 2023. Of the 473 patients screened, 392 were randomised (1:1) to receive study treatments. Baseline demographics and clinical characteristics were similar between groups (Table 1). The overall mean age of patients was 47.29 ± 8.87 years. The mean baseline HbA1c was 9.16% ± 0.75%. In accordance with the study eligibility criteria, no patient had an HbA1c < 7.0% at baseline. Treatment compliance in the 16‐week double‐blind period was 96.8% and 98.0% in the SITA + MET + GLIM and Co‐administration groups, respectively. Trial profile. FDC, fixed‐dose combination. TABLE 1Baseline demographics and clinical characteristics (safety population).Sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg a (n = 190)Metformin and glimepiride b (n = 202)Sex, n (%)Male102 (53.7%)121 (59.9%)Female88 (46.3%)81 (40.1%)Age, years, mean ± SD47.57 ± 8.5747.01 ± 9.16Height, cm, mean ± SD162.8 ± 7.68163.5 ± 8.87Weight, kg, mean ± SD67.51 ± 9.9369.16 ± 10.34BMI, kg/m2, mean ± SD25.49 ± 3.6125.95 ± 3.87HbA1c, %, mean ± SD9.18 ± 0.759.14 ± 0.74HbA1c, %, median (range)8.93 (8.00–11.00)8.95 (8.00–11.00)HbA1c, mmol/mol, mean ± SD76.82 ± 8.2376.36 ± 8.12FBG, mg/dL, mean ± SD177.16 ± 38.31183.89 ± 40.30PPBG, mg/dL, mean ± SD253.45 ± 54.83253.57 ± 61.90 Note: The safety population included all enrolled patients who received at least one dose of study medication.Abbreviations: BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; PPBG, post‐prandial blood glucose; SD, standard deviation. a Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. b Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily. Baseline demographics and clinical characteristics (safety population). Note: The safety population included all enrolled patients who received at least one dose of study medication. Abbreviations: BMI, body mass index; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; PPBG, post‐prandial blood glucose; SD, standard deviation. Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily. Of the 190 patients randomised to the SITA + MET + GLIM group, 182 entered the 12‐week, open‐label treatment period. Of these, 130 patients continued to receive the same dose (sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg) BID, and 52 received the up‐titrated dose (sitagliptin 50 mg/metformin 1000 mg/glimepiride 2 mg) BID at Week 16. Efficacy The mean (SD) change in HbA1c from baseline to Week 16 was significantly greater in patients in the SITA + MET + GLIM group than in the Co‐administration group [−1.79% (0.98) vs. −1.28% (0.89), respectively; p < 0.0001]. The least‐squares mean change in HbA1c from baseline to Week 16 was significant in both groups. However, it was significantly greater in the SITA + MET + GLIM group than the Co‐administration group (p < 0.0001; Table 2, Figure 2A). The proportion of patients with HbA1c < 7% at Week 12 was similar between the two groups, but significantly greater at Week 16 for those receiving SITA + MET + GLIM compared to co‐administration of metformin and high‐dose glimepiride [32.1% vs. 12.6%, respectively; p < 0.0001] (Figure 2B). TABLE 2Primary and secondary efficacy endpoints during the 16‐week double‐blind treatment period (mITT population).EndpointsSitagliptin 50 mg, metformin 1000 mg and glimepiride 1 mg a (n = 190)Metformin and glimepiride b (n = 202)ETD (95% CI) p HbA1c, %, mean ± SD (primary endpoint)Baseline9.18% ± 0.75%9.14% ± 0.74% p = 0.57 d Week 16 c 7.39% ± 1.01%7.86% ± 0.97%Change from baseline, mean ± SD−1.79% ± 0.98%−1.28% ± 0.89%Change from baseline, LS mean (SE)−1.79 (0.07)%−1.27 (0.06)%−0.51 (−0.69% to −0.33)% p < 0.0001 d Patients with HbA1c < 7.0%, n (%)Week 12 d 37 (19.8%)40 (20.1%) p = 0.94 e Week 16 c 60 (32.1%)25 (12.6%) p < 0.0001 e FBG, mg/dL, mean ± SDBaseline175.1 ± 38.36181.7 ± 42.35 p = 0.11 f Week 12 d 142.2 ± 33.53146.0 ± 34.72Change from baseline, mean ± SD−32.6 ± 37.54−35.6 ± 37.89Change from baseline, LS mean (SE)−34.61 (2.13)−33.76 (2.07)−0.85 (−6.69, 4.99) p = 0.78 f Week 16 c 133.7 ± 30.80141.1 ± 32.66Change from baseline, mean ± SD−41.1 ± 38.97−40.2 ± 40.43Change from baseline, LS mean (SE)−43.13 (2.13)−38.34 (2.07)−4.78 (−10.63, 1.06) p = 0.11PPBG, mg/dL, mean ± SDBaseline247.1 ± 53.17253.4 ± 62.44 p = 0.28 f Week 12 d 204.4 ± 49.13208.2 ± 47.03Change from baseline, mean ± SD−41.8 ± 53.00−44.7 ± 59.99Change from baseline, LS mean (SE)−44.57 (3.03)−42.59 (2.94)−1.98 (−10.28, 6.31) p = 0.64 f Week 16 c 189.6 ± 41.12193.0 ± 40.72Change from baseline, mean ± SD−56.7 ± 51.80−59.7 ± 59.96Change from baseline, LS mean (SE)−59.46 (3.03)−57.39 (2.95)−2.07 (−10.37, 6.23) p = 0.62 f Note: The double‐blind treatment period was from baseline to the end of Week 16. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit.Abbreviations: ETD, estimated treatment difference; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; LS, least squares; mITT, modified intention‐to‐treat; MMRM, mixed model for repeated measures. PPBG, post‐prandial blood glucose; SD, standard deviation; SE, standard error. a Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. b Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily. c Data on some variables were not available for all patients. Endpoints at Week 16 were assessed in 187 patients receiving sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg and 198 patients in the metformin and glimepiride group. d Endpoints at Week 12 were assessed in 187 patients in the sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg treatment group and in 199 patients in the metformin and glimepiride group. e Between‐treatment‐group comparison based on chi‐squared test. f Baseline p‐values are based on a paired t‐test. p‐values for treatment differences at Week 12 are based on an MMRM including change in HbA1c, FBG or PPBG as the dependent variable and treatment, visit, and treatment by visit interaction as fixed effects and baseline HbA1c, FBG or PPBG as a covariate. p < 0.05 was considered significant. Primary and secondary efficacy endpoints during the 16‐week double‐blind treatment period (mITT population). Note: The double‐blind treatment period was from baseline to the end of Week 16. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit. Abbreviations: ETD, estimated treatment difference; FBG, fasting blood glucose; HbA1c, glycated haemoglobin; LS, least squares; mITT, modified intention‐to‐treat; MMRM, mixed model for repeated measures. PPBG, post‐prandial blood glucose; SD, standard deviation; SE, standard error. Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily. Data on some variables were not available for all patients. Endpoints at Week 16 were assessed in 187 patients receiving sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg and 198 patients in the metformin and glimepiride group. Endpoints at Week 12 were assessed in 187 patients in the sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg treatment group and in 199 patients in the metformin and glimepiride group. Between‐treatment‐group comparison based on chi‐squared test. Baseline p‐values are based on a paired t‐test. p‐values for treatment differences at Week 12 are based on an MMRM including change in HbA1c, FBG or PPBG as the dependent variable and treatment, visit, and treatment by visit interaction as fixed effects and baseline HbA1c, FBG or PPBG as a covariate. p < 0.05 was considered significant. Glycaemic outcomes during the double‐blind treatment period (mITT population) (A) Mean glycated haemoglobin (HbA1c), change from baseline to Week 16. (B) Proportion of patients with HbA1c below 7% at Week 12 and Week 16. n represents the number of patients in each treatment group. The double‐blind treatment period was from baseline to the end of Week 16. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit. CI, confidence interval; HbA1c, glycated haemoglobin; mITT, modified intention‐to‐treat. *Triple fixed‐dose combination of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg twice daily. †Co‐administration of metformin hydrochloride 500 mg (two tablets) and glimepiride 2 mg twice daily. Mean FBG and PPBG concentrations decreased from baseline to Weeks 12 and 16 in both groups (Table 2). These reductions were significant within each group and similar between groups. The change in HbA1c [mean (SD)] from baseline to end of the open‐label treatment period (Week 28) was −2.37% (1.04) in the pooled population receiving triple FDCs (sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 or 2 mg; n = 182) (Table 3). At Week 28, 53.0% of patients who entered the 12‐week open‐label treatment period had achieved < 7% HbA1c. PPBG levels [mean (SD)] continued to decrease from baseline in the open‐label treatment period. Patients receiving triple FDCs achieved reductions from baseline in PPBG [−72.8 (55.60) mg/dL at Week 24 and −78.6 (57.25) mg/dL at Week 28] and FBG [−48.4 (40.75) mg/dL at Week 24 and −53.6 (41.74) mg/dL at Week 28]. TABLE 3Secondary efficacy endpoints during the 12‐week open‐label treatment period (mITT population).Secondary endpointsSitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg or 2 mg a (n = 182)Change from baselineHbA1c, %, mean ± SDBaseline9.16 ± 0.74Week 247.06 ± 1.01−2.10 ± 0.99, p < 0.0001 c Week 28 b 6.79 ± 1.03−2.37 ± 1.04, p < 0.0001 c Patients with HbA1c < 7.0%, n (%)Week 2896 (53.0%)NAFBG, mg/dL, mean ± SDBaseline176.7 ± 38.04Week 24128.2 ± 26.79−48.4 ± 40.75, p < 0.0001 c Week 28 b 123.2 ± 25.95−53.6 ± 41.74, p < 0.0001 c PPBG, mg/dL, mean ± SDBaseline251.1 ± 53.91Week 24178.3 ± 35.62−72.8 ± 55.60, p < 0.0001 c Week 28 b 172.4 ± 38.64−78.6 ± 57.25, p < 0.0001 c Note: The open‐label treatment period was from the end of Week 16 to the end of Week 28. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit.Abbreviations: FBG, fasting blood glucose; FDC, fixed‐dose combination; mITT, modified intention‐to‐treat; NA, not applicable; PPBG, post‐prandial blood glucose; SD, standard deviation. a Triple FDC of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg (if HbA1c < 8% at Week 16) or triple FDC of sitagliptin 50 mg, metformin 1000 mg, and glimepiride 2 mg (if HbA1c ≥ 8% at Week 16). b Endpoints at Week 28 were assessed in 181 patients. c Change from baseline values were analysed using Wilcoxon signed rank test for within‐group comparison. p < 0.05 was considered significant. Secondary efficacy endpoints during the 12‐week open‐label treatment period (mITT population). Note: The open‐label treatment period was from the end of Week 16 to the end of Week 28. The mITT population included all enrolled patients who were administered at least one dose of study medication and returned for at least one post‐baseline evaluation visit. Abbreviations: FBG, fasting blood glucose; FDC, fixed‐dose combination; mITT, modified intention‐to‐treat; NA, not applicable; PPBG, post‐prandial blood glucose; SD, standard deviation. Triple FDC of sitagliptin phosphate 50 mg, metformin hydrochloride 1000 mg, and glimepiride 1 mg (if HbA1c < 8% at Week 16) or triple FDC of sitagliptin 50 mg, metformin 1000 mg, and glimepiride 2 mg (if HbA1c ≥ 8% at Week 16). Endpoints at Week 28 were assessed in 181 patients. Change from baseline values were analysed using Wilcoxon signed rank test for within‐group comparison. p < 0.05 was considered significant. A post hoc subgroup analysis of results from the open‐label treatment period based on glimepiride dose showed that the 130 patients who received SITA + MET + GLIM had mean (SD) HbA1c levels of 8.97% (0.61) at baseline and 6.93% (0.75) at the end of Week 16. Overall mean (SD) change in HbA1c from baseline to Week 28 was −2.53% (0.95), including a reduction of −0.50% (0.58) from Week 16 to Week 28 (p < 0.0001). The 52 patients who received sitagliptin 50 mg/metformin 1000 mg/glimepiride 2 mg in the open‐label treatment period had mean (SD) HbA1c levels of 9.64% (0.83) at baseline and 8.51% (0.64) at the end of Week 16. Overall change in HbA1c from baseline to Week 28 was −1.97% (1.14), including a reduction of −0.84% (0.69) from Week 16 to Week 28 when patients received the higher dose (p < 0.0001) (Figure S2). Safety During the double‐blind treatment period, 67 treatment‐emergent adverse events (TEAEs) were reported in 55 patients (14.0%) (Table S2). The incidence of TEAEs was comparable between the two groups, with 31 TEAEs in 25 patients (13.2%) in the SITA + MET + GLIM group and 36 TEAEs in 30 patients (14.9%) in the Co‐administration group. Of these, 28 TEAEs (12 and 16 TEAEs in SITA + MET + GLIM and Co‐administration groups, respectively) were determined by the investigator to be probably or possibly related to the study treatment. The most common TEAEs were headache (2.3%), pyrexia (2.0%), vomiting (2.0%), diarrhoea (2.0%), nausea (1.5%), hypoglycaemia (1.0%), upper abdominal pain (1.0%), myalgia (1.0%), nasopharyngitis (0.5%), gastritis (0.5%), cough (0.5%), rhinorrhoea (0.3%), arthralgia (0.3%), back pain (0.3%) and constipation (0.3%). Overall, most TEAEs were mild (n = 58) or moderate (n = 8) in severity. One severe TEAE (gastritis) observed in the co‐administration group was determined to be possibly related to study treatment and resolved after 2 days. Of the eight moderate TEAEs, two (muscle pain and fever) were reported in one patient in the SITA + MET + GLIM group, and six (four of fever and one each of back pain and vomiting) were reported in four patients in the co‐administration group. The vomiting event was possibly related to the study treatment. During the open‐label period, eight patients (4.4%) receiving triple FDCs (sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 or 2 mg) reported TEAEs. These TEAEs were mild and unlikely to be related to study treatments (Table S3). No serious AEs, deaths or life‐threatening TEAEs were reported during the study. No TEAEs resulted in dose reductions, interruption or discontinuation of study treatment. The proportion of patients with confirmed hypoglycaemia was similar in both groups during the double‐blind period. Five events were reported in three patients (1.6%) in the SITA + MET + GLIM group and two events in one patient (0.5%) in the Co‐administration group. One hypoglycaemia event was experienced during the open‐label period. All hypoglycaemia events were asymptomatic, mild and detected only by laboratory values, with no requirement for hypoglycaemia management. No patients required rescue medications during the study, and no additional safety concerns were observed. Discussion This first‐in‐world, large‐scale, Phase 3, randomised, active‐controlled study assessed the superiority of triple FDC of sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg BID with co‐administration of metformin 1000 mg and glimepiride 2 mg BID among Indian patients with poorly controlled T2D. Despite treatment with metformin (≥ 1500 mg/day) and high‐dose glimepiride (4 mg/day), patients enrolled in this study had a mean baseline HbA1c of 9.16%. Sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg BID treatment for 16 weeks demonstrated superior efficacy in reducing HbA1c from baseline compared with metformin 1000 mg and glimepiride 2 mg BID. The mean reduction in HbA1c from baseline to Week 16 observed in the SITA + MET + GLIM group was significantly greater than that of the co‐administration group. Further reductions in HbA1c levels were observed in patients receiving triple FDCs (sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 or 2 mg) during the 12‐week open‐label treatment period. Almost one‐third of patients in the SITA + MET + GLIM group had HbA1c < 7% at Week 16. This proportion was significantly higher than reported for the Co‐administration group (12.6%). Over half of all patients enrolled in the open‐label treatment period achieved HbA1c < 7% by Week 28. The triple FDCs had a favourable safety profile and were well tolerated in the study population. Furthermore, safety profiles of each treatment group were comparable throughout the study. Overall, the findings of this study align with previous pilot studies [14, 15]. However, HbA1c reduction in our study was higher than that previously reported after adding sitagliptin 50 mg to glimepiride regimens over 28 weeks (approximately −0.8% to −1.1%). This difference may be due to the higher baseline HbA1c in our study and the lower sitagliptin dose (50 mg/day) used in both pilot studies [14, 15]. The reduction of FBG from baseline to Week 16 aligns with the Sato et al. study [15]. Sitagliptin combined with low‐dose glimepiride reduced HbA1c levels without hypoglycaemia or weight gain compared to high‐dose glimepiride in the pilot studies [14, 15]. The incidence of hypoglycaemic events (two in the sitagliptin group and one in the glimepiride group) was low and mild in severity in the Sato et al. study [15]. In our study, patients were already receiving a high‐dose glimepiride (4 mg/day) and metformin before enrolment. The low incidence of hypoglycaemic events may be due to the potential tolerability of ongoing combination therapy. Real‐world data on the addition of sitagliptin compared with up‐titration of glimepiride in patients with T2D treated with standard‐dose glimepiride and metformin may reveal differences in hypoglycaemia events between these treatment approaches. Ishii et al. hypothesised that the sitagliptin and glimepiride combination may regulate insulin secretion in T2D to prevent beta‐cell exhaustion. The potential synergy mechanism could be based on glimepiride‐induced insulin release via KATP/sulfonylurea receptor channel activation, combined with a sitagliptin‐induced increase in cellular cAMP potentiating KATP channel‐independent insulinotropic action by glucose [17]. Sitagliptin with low‐dose glimepiride has also been shown to preserve beta‐cell function compared with high‐dose glimepiride [18]. In India, T2D prevalence is approaching epidemic proportions, with the added challenge of affecting a relatively young population and co‐existing co‐morbidities, including hypertension and dyslipidaemia [1, 9]. The Indian Council of Medical Research–India Diabetes study (ICMR‐INDIAB‐13) demonstrated that < 10% of patients with T2D achieve good “ABC” (HbA1c, blood pressure, and low‐density lipoprotein cholesterol) control [6]. It has been observed that a 1.0% increase in HbA1c significantly increases fatal/non‐fatal coronary heart disease (34%) and fatal/non‐fatal cardiovascular disease (32%) in patients with a mean baseline HbA1c of 7.2% [19]. Hence, a stringent approach to control glycaemic parameters is essential [18]. Polypharmacy is a major hurdle in implementing an intensive approach, with high pill burden being a main reason for poor adherence observed in almost one‐third of patients [7]. Sulfonylureas are the second most widely prescribed drug in T2D management in India [20]. However, it often requires dose escalation over time, leading to beta‐cell exhaustion and limited durability of therapeutic response. Higher sulfonylurea doses are often associated with adverse events, including hypoglycaemia and weight gain. Hence, adding a third drug to the treatment regimen instead of increasing the sulfonylurea dose may be suitable. The triple FDCs proved efficacious and safe with synergistic benefits in patients with uncontrolled T2D, surpassing the limitations of individual therapies. The strength of this study is the large‐scale, randomised, double‐blind, double‐dummy, active‐controlled trial design, which is the standard for assessing efficacy and safety of a treatment. The study showed better HbA1c control in the SITA + MET + GLIM group, with almost one‐third of patients achieving good glycaemic control after 16 weeks, without compromising safety. Sitagliptin 50 mg/metformin 1000 mg/glimepiride 1 mg may add value to T2D management by improving glycaemic control, potentially delaying deterioration of beta‐cell function, improving compliance and delaying complications. Overall, this may help improve productivity, decrease healthcare resource utilisation, and have a positive economic impact on society. However, this study has a few limitations. Firstly, the efficacy and safety of sitagliptin 50 mg/metformin 1000 mg/glimepiride 2 mg were assessed in only 52 patients who required up‐titration. Hence, studies evaluating the efficacy and safety of this high‐dose triple FDC in larger populations would be beneficial. Secondly, the study duration was only 28 weeks, emphasising the need for long‐term follow‐up studies (≥ 52 weeks) to assess the maintenance of therapeutic efficacy. In conclusion, this study demonstrated that the triple FDC is effective, well‐tolerated, and has the potential to reduce pill burden and improve adherence. Author Contributions Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebrao Patil, Ambrish C., Satish Babu K.N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo and Pradeep Kumar Rai enrolled participants and conducted the study. Piyush Patel, Lalit Lakhwani, Suyog Mehta, and Sadhna Joglekar were involved in planning and designing of the study. Raisa Shaikh, Shruti Saha, Dipak Patil, Pravin Ghadge and Suyog Mehta were involved in data review and preparation of the clinical study report. Shruti Saha was responsible for manuscript preparation. Raisa Shaikh directly accessed and verified the underlying data reported in the manuscript. All authors critically reviewed the manuscript and approved the final draft, had full access to all study data, and had final responsibility for the decision to submit for publication. All authors' views expressed in the article are the same as those held by Sun Pharma Laboratories Limited. Funding This work was supported by Sun Pharma Laboratories Limited. Conflicts of Interest Rakesh Sahay, Ambanna Gowda, Manish Kumar Singh, A. Gopal Rao, Ramesh Duraisamy, Dinesh Gangwani, Jitendra Shukla, Vikas Agarwal, Sandesh Sahebrao Patol, Ambrish C., Satish Babu K.N., Arvind Palawat, Sandip Krishnrao Gofne, Abhay Kumar Sahoo, and Pradeep Kumar Rai were the study investigators. Raisa Shaikh, Piyush Patel and Lalit Lakhwani were employed with Sun Pharma during the study. Shruti Saha, Dipak Patil, Pravin Ghadge and Suyog Mehta are full‐time employees of Sun Pharma. Sadhna Joglekar was an employee at Sun Pharma during the conduct of this study. She is currently employed with Novartis. The views expressed in the article are the author's views and do not necessarily reflect the views or official position of Novartis. Supporting information Table S1: List of study sites and ethics committee details. Table S2: On‐treatment adverse events during the double‐blind treatment period (safety population). Table S3: Summary of treatment‐emergent adverse events during the 12‐week open‐label treatment period (safety population). Figure S1: Trial design. Figure S2: Change in HbA1c from baseline through to Week 28 during the study treatment period (mITT population).